While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

The sensor-guided device delivers continuous hemodynamic measurements and rapid left ventricular pacing during TAVR procedures. Back in 2023, it was at the heart of a $253 million acquisition. 

Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning. 

TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.